Frequency of HER2 expression of circulating tumour cells in patients with metastatic or recurrent gastrointestinal cancer

British Journal of Cancer

Volumn 109, Issue 11, 2013, Pages 2829-2832

  Iwatsuki, M ^a   Toyoshima, K ^b   Watanabe, M ^a   Hayashi, N ^a   Ishimoto, T ^a   Eto, K ^a   Iwagami, S ^a   Baba, Y ^a   Yoshida, N ^a   Hayashi, A ^b   Ohta, Y ^b   Baba, H ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b Takeda Pharmaceutical Company Ltd   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; AUTOANALYZER; BONE METASTASIS; CANCER PATIENT; CIRCULATING TUMOR CELL; COLORECTAL CANCER; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; ESOPHAGUS CANCER; FEMALE; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENT CANCER; STOMACH CANCER; SYSTEMIC THERAPY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; RECEPTOR, ERBB-2; RECURRENCE; TUMOR MARKERS, BIOLOGICAL;

EID: 84888869013     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.680     Document Type: Article

References (16)

1. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AG, Uhr JW, Terstappen LW (2004) Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 10: 6897-6904. (Pubitemid 39383039)
2. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376: 687-697.
3. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocakova I, Ruff P, Blasinska-Morawiec M, Smakal M, Canon JL, Rother M, Oliner KS, Wolf M, Gansert J (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28: 4697-4705.
4. Fehm T, Muller V, Aktas B, Janni W, Schneeweiss A, Stickele R E, Lattrich C, Lohberg CR, Solomayer E, Rack B, Riethdorf S, Klein C, Schindlbeck C, Brocker K, Kasimir-Bauer S, Wallwiener D, Pantel K (2010) HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res Treat 124: 403-412.
5. Ignatiadis M, Rothe F, Chaboteaux C, Durbecq V, Rouas G, Criscitiello C, Metallo J, Kheddoumi N, Singhal SK, Michiels S, Veys I, Rossari J, Larsimont D, Carly B, Pestrin M, Bessi S, Buxant F, Liebens F, Piccart M, Sotiriou C (2011) HER2-positive circulating tumor cells in breast cancer. PLoS One 6: e15624.
6. Khan AN, Yang W, Seifalian AM, Winslet MC (2006) HER2 (ErbB2) receptors, a potential therapeutic target in squamous cell carcinoma of oesophagus. Br J Cancer 94: 1213-1214.
7. Meng S, Tripathy D, Shete S, Ashfaq R, Haley B, Perkins S, Beitsch P, Khan A, Euhus D, Osborne C, Frenkel E, Hoover S, Leitch M, Clifford E, Vitetta E, Morrison L, Herlyn D, Terstappen LW, FLEMING T, Fehm T, Tucker T, Lane N, Wang J, Uhr J (2004) HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci USA 101: 9393-9398. (Pubitemid 38812885)
8. Nathanson DR, Culliford ATT, Shia J, Chen B, D'Alessio M, Zeng ZS, Nash GM, Gerald W, Barany F, Paty PB (2003) HER 2/neu expression and gene amplification in colon cancer. Int J Cancer 105: 796-802. (Pubitemid 36706103)
9. Negin BP, Cohen SJ (2010) Circulating tumor cells in colorectal cancer: past, present, and future challenges. Curr Treat Options Oncol 11: 1-13.
10. Pestrin M, Bessi S, Galardi F, Truglia M, Biggeri A, Biagioni C, Cappadona S, Biganzoli L, Giannini A, Di Leo A (2009) Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Res Treat 118: 523-530.
11. Riethdorf S, Muller V, Zhang L, Rau T, Loibl S, Komor M, Roller M, Huober J, Fehm T, Schrader I, Hilfrich J, Holms F, Tesch H, Eidtmann H, Untch M, Von Minckwitz G, Pantel K (2010) Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant Gepar Quattro trial. Clin Cancer Res 16: 2634-2645.
12. Rink M, Chun FK, Dahlem R, Soave A, Minner S, Hansen J, Stoupiec M, Coith C, Kluth LA, Ahyai SA, Friedrich MG, Shariat SF, Fisch M, Pantel K, Riethdorf S (2012) Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study. Eur Urol 61: 810-817.
13. Ruschoff J, Dietel M, Baretton G, Arbogast S, Walch A, Monges G, Chenard MP, Penault-Llorca F, Nagelmeier I, Schlake W, Hofler H, Kreipe HH (2010) HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch 457: 299-307.
14. Shinozaki E, Yamamoto N, Chin K, Ogura M, Suenaga M, Matsusaka S, Mizunuma N, Toshiharu Y, Hatake K (2012) How many biopsy fragments will be necessary to assess HER2 status for gastric cancer? J Clin Oncol 30(suppl 4): abstr 40.
15. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pinter T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360: 1408-1417.
16. Warneke VS, Behrens HM, Boger C, Becker T, Lordick F, Ebert MP, Rocken C (2012) Her2/neu testing in gastric cancer: evaluating the risk of sampling errors. Ann Oncol. 24(3): 725-733.